Abatacept (Synonyms: CTLA4lg; BMS-188667) |
| Catalog No.GC38130 |
Abatacept (CTLA4lg) es una proteína de fusión soluble que consiste en el dominio extracelular del CTLA4 humano y un fragmento de la porción Fc del IgG1 humano (bisagra y los dominios CH2 y 3).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 332348-12-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Abatacept (CTLA4Ig) is a soluble fusion protein composed of the extracellular domain of human cytotoxic T lymphocyte-associated protein 4 (CTLA4) and a fragment of the human IgG1 Fc portion (hinge, CH2 and 3 domains)[1]. Abatacept is a selective T cell co-stimulatory modulator and a protein drug used to treat autoimmune diseases[2]. CTLA4 is structurally similar to CD28, but binds to CD80 and CD86 with higher affinity, thereby inhibiting T cell activation[3]. Abatacept can be used to treat moderate to severe rheumatoid arthritis (RA), and is also used to treat psoriatic arthritis and juvenile idiopathic arthritis[4].
In vitro, Abatacept (0.5, 5, 50μM) treatment of human Burkitt lymphoma B (BJAB) wild-type, CD80 KO, and CD86 KO cells for 2h reduced the expression of CD86 and CD80 on the cell surface[5].
In vivo, subcutaneous administration of Abatacept (10mg/kg, once every 2 days) to DO11.10 RAG-2–/– mice inhibited T cell activation in the draining lymph nodes of mice, but did not induce T cell anergy or the generation of Treg cells[6]. Subcutaneous administration of Abatacept (20mg/kg) to rats with collagen-induced arthritis (CIA) significantly reduced paw edema[7].
References:
[1] Douthwaite J, Moisan J, Privezentzev C, et al. A CD80-biased CTLA4-Ig fusion protein with superior in vivo efficacy by simultaneous engineering of affinity, selectivity, stability, and FcRn binding[J]. The Journal of Immunology, 2017, 198(1): 528-537.
[2] Chitale S, Moots R. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis[J]. Expert opinion on biological therapy, 2008, 8(1): 115-122.
[3] da Rosa L C, Scales H E, Benson R A, et al. The effect of abatacept on T-cell activation is not long-lived in vivo[J]. Discovery Immunology, 2024, 3(1): kyad029.
[4] Brunner H I, Wong R, Nys M, et al. Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis[J]. Pediatric Drugs, 2020, 22: 653-672.
[5] Lorenzetti R, Janowska I, Smulski C R, et al. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells[J]. Journal of Autoimmunity, 2019, 101: 145-152.
[6] Patakas A, Ji R R, Weir W, et al. Abatacept inhibition of T cell priming in mice by induction of a unique transcriptional profile that reduces their ability to activate antigen‐presenting cells[J]. Arthritis & rheumatology, 2016, 68(3): 627-638.
[7] Lon H K, Liu D, DuBois D C, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach[J]. Journal of pharmacokinetics and pharmacodynamics, 2013, 40: 701-712.
| Cell experiment [1]: | |
Cell lines | Human Burkitt lymphoma B (BJAB) wild type (WT)、CD80 KO、CD86 KO cells |
Preparation Method | BJAB wild type (WT), CD80 KO and CD86 KO cells were treated with Abatacept (10μg/mL) for 2h and CD86 and CD80 expression as sessed by flow cytometry prior removal of bound abatacept by acidic elution. |
Reaction Conditions | 10μg/mL; 2h |
Applications | Reduction in surface expression of CD86 and CD80 on human B-cells in the presence of Abatacept. |
| Animal experiment [2]: | |
Animal models | DO11.10 RAG-2–/– mice |
Preparation Method | To prime CD41 T cells, DO11.10 RAG-2–/– mice were injected subcutaneously in the scruff of the neck with 100 mg of OVA in Freund’s complete adjuvant. Mice were treated with 10mg/kg of Abatacept or control IgG beginning 2 days before priming and continuing every 2 days thereafter. |
Dosage form | 10mg/kg; s.c. |
Applications | Abatacept reduced the proportion of activated T cells (CD44highCD62L–) and inhibited the upregulation of ICOS and CD71. Cells primed in the presence of Abatacept produced substan tial amounts of IL-2, similar to the naive T cells, where as cells from orally tolerized mice produced very low levels of the cytokine, confirming their anergic state. |
References: | |
| Cas No. | 332348-12-6 | SDF | |
| Sinónimos | CTLA4lg; BMS-188667 | ||
| Canonical SMILES | [Abatacept] | ||
| Formula | M.Wt | ||
| Solubility | Soluble in water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *